Oxidation of LDL and its clinical implication

Autoimmunity Reviews

Volumn 7, Issue 7, 2008, Pages 558-566

  Matsuura, Eiji ^a   Hughes, Graham R V ^b   Khamashta, Munther A ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; IN VITRO STUDY; LIPID PEROXIDATION; NONHUMAN; OXIDATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; C-REACTIVE PROTEIN; HUMANS; LIPOPROTEINS, LDL; MICE;

EID: 50949112988     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.04.018     Document Type: Review

References (40)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
2. Hughes G.R.V., Harris N.N., and Gharavi A.E. The anticardiolipin syndrome. J Rheumatol 13 (1986) 486-489
3. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Suzuki T., Sumida T., et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148 (1992) 3885-3891
4. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179 (1994) 457-462
5. 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107 (1997) 569-573
6. 2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42 (2001) 697-709
7. 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44 (2003) 716-726
8. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 45 (2006) 466-486
9. Lopez D., Kobayashi K., Merrill J.T., Matsuura E., and Lopez L.R. IgG autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 10 (2003) 203-211
10. Shoenfeld Y., Wu R., Dearing L.D., and Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110 (2004) 2552-2558
11. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99 (2002) 13043-13048
12. Tabuchi M., Inoue K., Usui-Kataoka H., Kobayashi K., Teramoto M., Takasugi K., et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 48 (2007) 768-781
13. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
14. Witztum J.L., and Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 11 (2001) 93-102
15. Greaves D.R., and Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 46 (2005) 11-20
16. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93 (1998) 229-240
17. Itabe H., Takeshima E., Iwasaki H., Kimura J., Yoshida Y., Imanaka T., et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 269 (1994) 15274-15279
18. Friedman P., Horkko S., Steinberg D., Witztum J.L., and Dennis E.A. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J Biol Chem 277 (2002) 7010-7020
19. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18 (1999) 5166-5174
20. 2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 43 (2002) 1486-1495
21. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 (2001) 189-197
22. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
23. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
24. van Tits L., de Graaf J., Toenhake H., van Heerde W., and Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 25 (2005) 717-722
25. Calabro P., Willerson J.T., and Yeh E.T.H. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
26. Venugopal S.K., Devaraj S., and Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166 (2005) 1265-1271
27. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
28. 2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 121 (2004) 426-436
29. 2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann NY Acad Sci 1051 (2005) 97-103
30. 2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 98 (2004) c15-c24
31. Moorhead J.F., Chan M.K., El-Nahas M., and Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2 (1982) 1309-1311
32. Roh D.D., Kamanna V.S., and Kirschenbaum M.A. Oxidative modification of low-density lipoprotein enhances mesangial cell protein synthesis and gene expression of extracellular matrix proteins. Am J Nephrol 18 (1998) 344-350
33. 2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 1051 (2005) 313-322
34. Hashimoto Y., Kawamura M., Ichikawa K., Suzuki T., Sumida T., Yoshida S., et al. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 149 (1992) 1063-1068
35. Palinski W., Hörkko S., Miller E., Steinbrecher U.P., Powell H.C., Curtiss L.K., et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98 (1996) 800-814
36. Shaw P.X., Hörkko S., Chang M.K., Curtiss L.K., Palinski W., Silverman G.J., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 (2000) 1731-1740
37. Hörkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103 (1999) 117-128
38. Hörkko S., Binder C.J., Shaw P.X., Chang M.K., Silverman G., Palinski W., et al. Immunological responses to oxidized LDL. Free Radic Biol Med 28 (2000) 1771-1779
39. Erkkila A.T., Narvanen O., Lehto S., Uusitupa M.I., and Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 204-209
40. Ylä-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., and Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14 (1994) 32-40